Author:
Nozawa Masahiro,Mukai Hirofumi,Takahashi Shunji,Uemura Hiroji,Kosaka Takeo,Onozawa Yusuke,Miyazaki Jun,Suzuki Kazuhiro,Okihara Koji,Arai Yoichi,Kamba Tomomi,Kato Masashi,Nakai Yasutomo,Furuse Hiroshi,Kume Haruki,Ide Hisamitsu,Kitamura Hiroshi,Yokomizo Akira,Kimura Takahiro,Tomita Yoshihiko,Ohno Keiji,Kakehi Yoshiyuki
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Reference19 articles.
1. Center for Cancer Control and Information Services, National Cancer Center (2013) Cancer Statistics in Japan ′13. http://ganjoho.jp/pro/statistics/en/backnumber/2013_en.html . Accessed March 2015
2. Ferlay J, Soerjomataram I, Ervik M, et al (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and mortality worldwide: IARC cancer base No. 11. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr . Accessed March 2015
3. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12:1665–1671
4. Berthold, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242–245
5. Mukherji D, Omlin A, Pezaro C et al (2014) Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics. Cancer Metastasis Rev 33:555–566